IMUC
Price
$0.07
Change
-$0.03 (-30.00%)
Updated
Jul 2 closing price
Capitalization
8.99M
TNXP
Price
$35.48
Change
+$0.31 (+0.88%)
Updated
Jul 3 closing price
Capitalization
261.03M
38 days until earnings call
Interact to see
Advertisement

IMUC vs TNXP

Header iconIMUC vs TNXP Comparison
Open Charts IMUC vs TNXPBanner chart's image
EOM Pharmaceutical Holdings
Price$0.07
Change-$0.03 (-30.00%)
Volume$515
Capitalization8.99M
Tonix Pharmaceuticals Holding
Price$35.48
Change+$0.31 (+0.88%)
Volume$277.51K
Capitalization261.03M
IMUC vs TNXP Comparison Chart in %
Loading...
IMUC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TNXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMUC vs. TNXP commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMUC is a Hold and TNXP is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (IMUC: $0.07 vs. TNXP: $35.48)
Brand notoriety: IMUC and TNXP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMUC: 13% vs. TNXP: 29%
Market capitalization -- IMUC: $8.99M vs. TNXP: $261.03M
IMUC [@Biotechnology] is valued at $8.99M. TNXP’s [@Biotechnology] market capitalization is $261.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMUC’s FA Score shows that 1 FA rating(s) are green whileTNXP’s FA Score has 2 green FA rating(s).

  • IMUC’s FA Score: 1 green, 4 red.
  • TNXP’s FA Score: 2 green, 3 red.
According to our system of comparison, TNXP is a better buy in the long-term than IMUC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMUC’s TA Score shows that 1 TA indicator(s) are bullish while TNXP’s TA Score has 4 bullish TA indicator(s).

  • IMUC’s TA Score: 1 bullish, 5 bearish.
  • TNXP’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, TNXP is a better buy in the short-term than IMUC.

Price Growth

IMUC (@Biotechnology) experienced а -30.09% price change this week, while TNXP (@Biotechnology) price change was -0.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

IMUC is expected to report earnings on Nov 20, 2024.

TNXP is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TNXP($261M) has a higher market cap than IMUC($8.99M). TNXP has higher P/E ratio than IMUC: TNXP (0.10) vs IMUC (0.02). TNXP YTD gains are higher at: 7.580 vs. IMUC (-57.879). IMUC has higher annual earnings (EBITDA): -5.65M vs. TNXP (-66.23M). TNXP has more cash in the bank: 132M vs. IMUC (85.3K). TNXP has higher revenues than IMUC: TNXP (10M) vs IMUC (0).
IMUCTNXPIMUC / TNXP
Capitalization8.99M261M3%
EBITDA-5.65M-66.23M9%
Gain YTD-57.8797.580-764%
P/E Ratio0.020.1019%
Revenue010M-
Total Cash85.3K132M0%
Total DebtN/A563K-
FUNDAMENTALS RATINGS
IMUC vs TNXP: Fundamental Ratings
IMUC
TNXP
OUTLOOK RATING
1..100
5654
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
25
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9643
P/E GROWTH RATING
1..100
10016
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMUC's Valuation (10) in the Biotechnology industry is in the same range as TNXP (25) in the Pharmaceuticals Other industry. This means that IMUC’s stock grew similarly to TNXP’s over the last 12 months.

IMUC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as TNXP (100) in the Pharmaceuticals Other industry. This means that IMUC’s stock grew similarly to TNXP’s over the last 12 months.

TNXP's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as IMUC (100) in the Biotechnology industry. This means that TNXP’s stock grew similarly to IMUC’s over the last 12 months.

TNXP's Price Growth Rating (43) in the Pharmaceuticals Other industry is somewhat better than the same rating for IMUC (96) in the Biotechnology industry. This means that TNXP’s stock grew somewhat faster than IMUC’s over the last 12 months.

TNXP's P/E Growth Rating (16) in the Pharmaceuticals Other industry is significantly better than the same rating for IMUC (100) in the Biotechnology industry. This means that TNXP’s stock grew significantly faster than IMUC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMUCTNXP
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
IMUC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TNXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARZGF35.19N/A
N/A
Assicurazioni Generali Spa
CCHI0.17N/A
N/A
Cambridge Capital Holdings, Inc.
SILEF0.16N/A
N/A
Silver Elephant Mining Corp.
BGLAF9.58N/A
N/A
Biogaia AB
ATGFF28.39-0.11
-0.39%
AltaGas Ltd.

IMUC and

Correlation & Price change

A.I.dvisor tells us that IMUC and GRCE have been poorly correlated (+7% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IMUC and GRCE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMUC
1D Price
Change %
IMUC100%
N/A
GRCE - IMUC
7%
Poorly correlated
+3.64%
TNXP - IMUC
6%
Poorly correlated
+0.88%
SRPT - IMUC
5%
Poorly correlated
+0.25%
ORMP - IMUC
5%
Poorly correlated
+0.93%
PTCT - IMUC
4%
Poorly correlated
-0.16%
More

TNXP and

Correlation & Price change

A.I.dvisor indicates that over the last year, TNXP has been closely correlated with ICU. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if TNXP jumps, then ICU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TNXP
1D Price
Change %
TNXP100%
+0.88%
ICU - TNXP
77%
Closely correlated
-1.11%
NEVPF - TNXP
40%
Loosely correlated
N/A
TOVX - TNXP
35%
Loosely correlated
-1.56%
CRVS - TNXP
32%
Poorly correlated
-0.75%
RNAZ - TNXP
28%
Poorly correlated
+1.93%
More